ライフサイエンスコーパス: hepatocellular

1 d glucose homeostasis and long-term risks of hepatocellular adenoma (HCA) and carcinoma (HCC).

2 , myeloid dysfunction, and long-term risk of hepatocellular adenoma (HCA).

3 BACKGROUND & AIMS: Hepatocellular adenomas (HCAs) are benign liver tumors t

4 Hepatocellular adenomas (HCAs) are rare benign tumors di

5 tumors, mainly hematologic malignancies and hepatocellular adenomas and carcinomas.

6 ved livers functioned better and showed less hepatocellular and endothelial cell injury, in agreement

7 most promising candidate identified was the hepatocellular and renal cell carcinoma drug sorafenib.

8 d is highly up-regulated in many colorectal, hepatocellular, and ovarian cancers.

9 In addition, hepatocellular apoptosis, as determined by M30 levels, o

10 ecal bile salt loss, and expression of major hepatocellular bile salt transporters and cytochrome P45

11 BACKGROUND AND AIMS: The risk of hepatocellular cancer (HCC) after sustained virological

12 ut the best approach to select patients with hepatocellular cancer (HCC) waiting for liver transplant

13 lase (ACC) genes and treat the mice with the hepatocellular carcinogen diethylnitrosamine (DEN).

14 Gab2 mediates hepatocellular carcinogenesis by integrating multiple si

15 6 classic signaling, is essential to promote hepatocellular carcinogenesis by two mechanisms: First,

16 the mechanistic link between microbiota and hepatocellular carcinogenesis using a streptozotocin-hig

17 c signaling, is mandatory for development of hepatocellular carcinogenesis.

18 BACKGROUND & AIMS: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a primary liver can

19 the signature genetic event of fibrolamellar hepatocellular carcinoma (FL-HCC), a rare but lethal liv

20 was associated with a decreased incidence of hepatocellular carcinoma (hazard ratio [HR] compared wit

21 centage of patients with CLF from NASH), and hepatocellular carcinoma (HCC) (decreases in percentages

22 g-term outcomes of patients with early-stage hepatocellular carcinoma (HCC) after radiofrequency abla

23 n used to treat intrahepatic recurrent small hepatocellular carcinoma (HCC) against the diaphragmatic

24 reatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sus

25 ol mouse livers, as well as in matched human hepatocellular carcinoma (HCC) and benign liver tissue t

26 es have identified hepatic tumors with mixed hepatocellular carcinoma (HCC) and cholangiocarcinoma (C

27 s (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments fo

28 ntify differentially methylated enhancers in hepatocellular carcinoma (HCC) and experimentally confir

29 re they are a growing cause of cirrhosis and hepatocellular carcinoma (HCC) and increasingly an indic

30 : Little is known about the absolute risk of hepatocellular carcinoma (HCC) and liver-disease related

31 with cirrhosis increases early detection of hepatocellular carcinoma (HCC) and prolongs survival.

32 ackground of high morbidity and mortality of hepatocellular carcinoma (HCC) and rapid development of

33 Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate

34 of cirrhotic nodules and early diagnosis of hepatocellular carcinoma (HCC) are of vital importance.

35 Here, using hepatocellular carcinoma (HCC) as a cancer model, we hav

36 Patients with hepatocellular carcinoma (HCC) can receive Model for End

37 roliferation and induce cell cycle arrest in hepatocellular carcinoma (HCC) cell lines.

38 e et al ( 1 ) describe a unique mechanism of hepatocellular carcinoma (HCC) cells for surviving ische

39 Hepatocellular carcinoma (HCC) cells often invade the po

40 Purpose To characterize hepatocellular carcinoma (HCC) cells surviving ischemia

41 Application of DEIsoM to an hepatocellular carcinoma (HCC) dataset identifies biolog

42 DCEMRI) and contrast-enhanced CT (DCECT) for hepatocellular carcinoma (HCC) detection.

43 ipid homeostasis was also shown to attenuate hepatocellular carcinoma (HCC) development, thus implica

44 f treatment in patients developing recurrent hepatocellular carcinoma (HCC) following liver transplan

45 Surveillance by ultrasonography for hepatocellular carcinoma (HCC) for individuals with cirr

46 em (LI-RADS) version 2014 in differentiating hepatocellular carcinoma (HCC) from non-HCC malignancy i

47 inical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalued due

48 on between AAV2 integration events and human hepatocellular carcinoma (HCC) has generated controversy

49 ed method for the diagnosis and prognosis of hepatocellular carcinoma (HCC) has not yet been develope

50 Hepatocellular carcinoma (HCC) has the second lowest 5-y

51 g CD4(+) and CD8(+) T cells in patients with hepatocellular carcinoma (HCC) have been found to be fun

52 ve the efficacy of radiation therapy against hepatocellular carcinoma (HCC) have been investigated.

53 ROUND & AIMS: The incidence and mortality of hepatocellular carcinoma (HCC) have been reported to be

54 nd increased expression of FAM83H and MYC in hepatocellular carcinoma (HCC) have been reported.

55 eping beauty transposon/transposase leads to hepatocellular carcinoma (HCC) in mice that corresponds

56 Statin use also decreases the risk of hepatocellular carcinoma (HCC) in patients with chronic

57 ) are both used for noninvasive diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosi

58 Concern has arisen about the development of hepatocellular carcinoma (HCC) in patients with hepatiti

59 Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepa

60 ts with Hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) involves components of vi

61 Hepatocellular carcinoma (HCC) is a common cancer that f

62 Hepatocellular carcinoma (HCC) is a major health threat

63 As prognosis of patients with metastatic hepatocellular carcinoma (HCC) is mainly determined by i

64 Hepatocellular carcinoma (HCC) is more prevalent in men

65 most frequent chromosomal structural loss in hepatocellular carcinoma (HCC) is of the short arm of ch

66 Hepatocellular carcinoma (HCC) is one of the most common

67 Hepatocellular carcinoma (HCC) is one of the most deadly

68 Hepatocellular carcinoma (HCC) is one of the most freque

69 Hepatocellular carcinoma (HCC) is one of the most preval

70 ntial diagnosis between intrahepatic CCA and hepatocellular carcinoma (HCC) is sometimes difficult.

71 Hepatocellular carcinoma (HCC) is the leading cause of d

72 Hepatocellular carcinoma (HCC) is the second leading cau

73 Hepatocellular carcinoma (HCC) is the second leading cau

74 Hepatocellular carcinoma (HCC) is the second-leading cau

75 Hepatocellular carcinoma (HCC) is the third leading caus

76 Hepatocellular carcinoma (HCC) is the third leading form

77 Hepatocellular carcinoma (HCC) is the third most deadly

78 estigated the possibility that patients with hepatocellular carcinoma (HCC) listed for liver transpla

79 survival (ITT-OS) of cirrhotic patients with hepatocellular carcinoma (HCC) listed for living donor l

80 tumor activity in in vitro and in vivo human hepatocellular carcinoma (HCC) model.

81 Hepatocellular carcinoma (HCC) occurs more frequently an

82 CGA RNA-seq data acquired from patients with hepatocellular carcinoma (HCC) on tumors samples and the

83 all-oral DAA regimen among HCV patients with hepatocellular carcinoma (HCC) or decompensated cirrhosi

84 nitially resectable and transplantable (R&T) hepatocellular carcinoma (HCC) patients, to try to obvia

85 eceptor is responsible for poor prognosis of hepatocellular carcinoma (HCC) patients.

86 ta) signaling pathway is a common feature of hepatocellular carcinoma (HCC) progression.

87 everal factors are associated with increased hepatocellular carcinoma (HCC) recurrence after liver tr

88 plant bridging locoregional therapy (LRT) on hepatocellular carcinoma (HCC) recurrence and survival a

89 lvage liver transplantation (SLT) in case of hepatocellular carcinoma (HCC) recurrence is an alternat

90 Hepatocellular carcinoma (HCC) represents the fifth-most

91 CKGROUND DATA: Salvage transplantation after hepatocellular carcinoma (HCC) resection is limited to p

92 t wait time before liver transplant (LT) for hepatocellular carcinoma (HCC) results in the inclusion

93 Individualized assessment of hepatocellular carcinoma (HCC) risk in chronic liver dis

94 correlation between HDM2 and HBx in clinical hepatocellular carcinoma (HCC) samples.

95 lance benefits when determining the value of hepatocellular carcinoma (HCC) screening programs.

96 y expressed in approximately 60-70% of human hepatocellular carcinoma (HCC) specimens.

97 patients with cirrhosis are nonadherent with hepatocellular carcinoma (HCC) surveillance recommendati

98 ), a p53 mutant frequently detected in human hepatocellular carcinoma (HCC) that is highly related to

99 er Genome Atlas, Oncomine, PrognoScan, and a hepatocellular carcinoma (HCC) tissue microarray.

100 ed transcriptome data from 242 patients with hepatocellular carcinoma (HCC) to search for gene signat

101 Hepatocellular carcinoma (HCC) typically results from a

102 A) in the treatment of unresectable solitary hepatocellular carcinoma (HCC) up to 3 cm.

103 Here, we interrogated these compartments in hepatocellular carcinoma (HCC) using high-dimensional pr

104 (RFA) for patients with inoperable localized hepatocellular carcinoma (HCC) who are eligible for both

105 in the treatment of patients with inoperable hepatocellular carcinoma (HCC) who are ineligible for th

106 Patients with hepatocellular carcinoma (HCC) who are listed for liver

107 gan Sharing (UNOS) database in patients with hepatocellular carcinoma (HCC) who meet Milan criteria b

108 e markers and tumor biology in patients with hepatocellular carcinoma (HCC) who were bridged to liver

109 are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses

110 al outcomes for patients with advanced-stage hepatocellular carcinoma (HCC) with portal vein thrombos

111 As proof of principle, we examined hepatocellular carcinoma (HCC), a cancer that is derived

112 growth factor receptor FGFR4 by FGF19 drives hepatocellular carcinoma (HCC), a disease with few, if a

113 Here we provide evidence that cells from hepatocellular carcinoma (HCC), a highly metastatic canc

114 Hepatocellular carcinoma (HCC), a primary malignancy of

115 rogression and reduce the risk of cirrhosis, hepatocellular carcinoma (HCC), and CHB-associated morta

116 ses from chronic HCV to fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and death.

117 velopment of end-stage liver disease (ESLD), hepatocellular carcinoma (HCC), and liver-related death

118 sAg), prevalent hepatic decompensation (HD), hepatocellular carcinoma (HCC), and those treated for HC

119 nriched and potentially clonally expanded in hepatocellular carcinoma (HCC), and we identified signat

120 kemia (T-ALL) and progressive development of hepatocellular carcinoma (HCC), both lethal diseases.

121 from three of the most common PLC subtypes: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC)

122 ease (NAFLD) represents an emerging cause of hepatocellular carcinoma (HCC), especially in non-cirrho

123 Primary liver cancer comprises hepatocellular carcinoma (HCC), intrahepatic cholangioca

124 nt role in the pathogenesis of cirrhosis and hepatocellular carcinoma (HCC), most cases of which are

125 ed by an unknown mechanism in poor prognosis hepatocellular carcinoma (HCC), often associated with ch

126 pha-fetoprotein (AFP), a serum biomarker for hepatocellular carcinoma (HCC), the assay has high purif

127 Angiogenesis plays an important role in hepatocellular carcinoma (HCC), the inhibition of which

128 In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibito

129 ts with metastatic adenocarcinoma and 5 with hepatocellular carcinoma (HCC), were examined.

130 ld and it is a common cause of cirrhosis and hepatocellular carcinoma (HCC).

131 e recognized as independent risk factors for hepatocellular carcinoma (HCC).

132 ion and functional analysis of patients with hepatocellular carcinoma (HCC).

133 nomogram derived from BCLC for patients with hepatocellular carcinoma (HCC).

134 actful copy number gains in E2F1 and E2F3 in hepatocellular carcinoma (HCC).

135 non-coding RNAs (lncRNAs) is dysregulated in hepatocellular carcinoma (HCC).

136 ation (TAE), a purely ischemic treatment for hepatocellular carcinoma (HCC).

137 rhosis and predisposes to the development of hepatocellular carcinoma (HCC).

138 ch on Cancer) Group 1 carcinogen that causes hepatocellular carcinoma (HCC).

139 itor approved for several cancers, including hepatocellular carcinoma (HCC).

140 ncogenic event in diverse cancers, including hepatocellular carcinoma (HCC).

141 its impact on OS in patients with metastatic hepatocellular carcinoma (HCC).

142 currence After Liver transplant" (MORAL) for hepatocellular carcinoma (HCC).

143 active therapy and outcomes of patients with hepatocellular carcinoma (HCC).

144 that displays hepatosteatosis progressing to hepatocellular carcinoma (HCC).

145 sible for hepatitis, fatty liver disease and hepatocellular carcinoma (HCC).

146 RISC, has been implicated as an oncogene in hepatocellular carcinoma (HCC).

147 us feature associated with cancer, including hepatocellular carcinoma (HCC).

148 erapeutic approved for treatment of advanced hepatocellular carcinoma (HCC).

149 tage Liver Disease (MELD) at WL was >/=15 or hepatocellular carcinoma (HCC).

150 s B and C viruses are risk factors for human hepatocellular carcinoma (HCC).

151 network to maintain liver size and suppress hepatocellular carcinoma (HCC).

152 hronic liver diseases (CLDs) predisposing to hepatocellular carcinoma (HCC).

153 ARID1A in the development and progression of hepatocellular carcinoma (HCC).

154 g SLK outcomes in patients undergoing LT for hepatocellular carcinoma (HCC).

155 n the cell surface of an HCV core-expressing hepatocellular carcinoma (HepG2) cell line or immortaliz

156 on-coding RNA (lincRNA) profiles compared to hepatocellular carcinoma (n = 263) and cholangiocarcinom

157 TZ-HFD) induced nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) murine model and com

158 urvival of patients treated for unresectable hepatocellular carcinoma (uHCC) with (90)Y transarterial

159 recommendation for surveillance of recurrent hepatocellular carcinoma after liver transplantation (LT

160 he CR were histologically verified; 80% were hepatocellular carcinoma and 20% were intrahepatic chola

161 ort that the lncRNA MALAT1 is upregulated in hepatocellular carcinoma and acts as a proto-oncogene th

162 ge (AIM, also called CD5L) prevents obesity, hepatocellular carcinoma and acute kidney injury.

163 dult liver transplantation for patients with hepatocellular carcinoma and cirrhotic livers.

164 : A 55 year old gentleman was diagnosed with hepatocellular carcinoma and concomitant chronic hepatit

165 w the tumor suppressor SIRT6 is regulated in hepatocellular carcinoma and establish the mechanism und

166 +) T lymphocytes, which prevent emergence of hepatocellular carcinoma and express a limited repertoir

167 tes inflammation and promotes development of hepatocellular carcinoma and other liver diseases.

168 ers refractory to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gad

169 tion is a major cause of liver cirrhosis and hepatocellular carcinoma and the leading indication for

170 , therapy has been extended to patients with hepatocellular carcinoma as well.

171 Purpose Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol

172 d diagnostic tools have enabled diagnosis of hepatocellular carcinoma based on noninvasive methods wi

173 survival status-for patients diagnosed with hepatocellular carcinoma between Aug 1, 2006, and April

174 hospitals who were prescribed sorafenib for hepatocellular carcinoma between January 2006 and April

175 enger RNA and fusion protein (114 kD) in the hepatocellular carcinoma cell line HUH7, as well as in l

176 ria in sesamol-induced effects using a human hepatocellular carcinoma cell line, HepG2 cells.

177 N2A1-FER fusions in human prostate cancer or hepatocellular carcinoma cells in vitro and in mouse xen

178 the cytotoxic action of sorafenib in murine hepatocellular carcinoma cells.

179 We therefore initiated an African hepatocellular carcinoma consortium aiming to describe t

180 er HBsAg positivity or viremia had recurrent hepatocellular carcinoma diagnosed within a month of det

181 decompensated cirrhosis from 12.2% to 4.5%, hepatocellular carcinoma from 9.1% to 4.0%, liver transp

182 ular carcinoma, and 3% of patients developed hepatocellular carcinoma from HCA.

183 policy strategies to decrease the burden of hepatocellular carcinoma in Africa.

184 n, management, and outcomes of patients with hepatocellular carcinoma in Africa.

185 Hepatitis C virus was the leading cause of hepatocellular carcinoma in Egypt (1054 [84%] of 1251 pa

186 elp explain the extraordinarily high rate of hepatocellular carcinoma in Mongolia.

187 ic disturbances and in the increased risk of hepatocellular carcinoma in patients with AAT deficiency

188 oderate alcohol use may increase the risk of hepatocellular carcinoma in patients with advanced fibro

189 atures were associated with a higher risk of hepatocellular carcinoma in patients with SVRs, but not

190 Hepatocellular carcinoma is a leading cause of cancer-re

191 Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminate

192 3A5 affects the metabolism and malignancy of hepatocellular carcinoma is unknown.

193 enzymes in 10 matched pericarcinomatous and hepatocellular carcinoma liver samples.

194 oreover, levels of M30 and M65 predicted non-hepatocellular carcinoma liver-related mortality in pati

195 hotics listed for liver transplantation with hepatocellular carcinoma MELD exception points.

196 in vitro and in a patient-derived orthotopic hepatocellular carcinoma model in mice.

197 rticles in combination with RF ablation in a hepatocellular carcinoma mouse model.

198 it would have been expected that the rate of hepatocellular carcinoma occurrence is markedly decrease

199 ith the AAV-BR1-CAG-NEMO vector developed no hepatocellular carcinoma or other major adverse effects

200 diseases, a grey area exists with regard to hepatocellular carcinoma or other tumour types in childr

201 Consistently, analysis of 160 hepatocellular carcinoma patient specimens indicated tha

202 n serum was higher (>8.5 fold, P < 0.001) in hepatocellular carcinoma patients compared to healthy an

203 In some hepatocellular carcinoma patients, ARID1A was highly exp

204 e surveillance imaging schedules for post-LT hepatocellular carcinoma patients.

205 tumor, and adjacent normal tissues from six hepatocellular carcinoma patients.

206 ss of liver transplantation in patients with hepatocellular carcinoma poorly estimate post-transplant

207 We also analyzed hepatocellular carcinoma samples and show these solid tu

208 sAg-positive patients with liver fibrosis or hepatocellular carcinoma was 5.24 (95% CI 2.74-10.01; p<

209 No evidence of hepatocellular carcinoma was detected.

210 decompensated liver disease, or a history of hepatocellular carcinoma were excluded.

211 ckpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral h

212 ears) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or

213 HL-60 (Human promyelocytic leukemia), HepG2 (Hepatocellular carcinoma) and MCF 12A (normal epithelial

214 X-E12 (colorectal adenocarcinoma) and HepG2 (hepatocellular carcinoma), were used to investigate the

215 or in the etiology of fibrosis/cirrhosis and hepatocellular carcinoma, although the mechanisms for th

216 p of 49 months, 6 patients died, 2 developed hepatocellular carcinoma, and 1 had liver failure, all o

217 the nodules were borderline between HCA and hepatocellular carcinoma, and 3% of patients developed h

218 620 patients with PCLD, 18 240 patients with hepatocellular carcinoma, and 98 567 patients with CLF.

219 f gastrointestinal tract cancers, especially hepatocellular carcinoma, and colorectal cancer.

220 haryngeal carcinoma (NPC), breast cancer and hepatocellular carcinoma, and contributes to NPC's resis

221 vere liver diseases, including cirrhosis and hepatocellular carcinoma, and is one of the most importa

222 for progression to cirrhosis, liver failure, hepatocellular carcinoma, and liver-related mortality.

223 transplantation are alcoholic liver disease, hepatocellular carcinoma, and viral hepatitis.

224 care for patients with advanced unresectable hepatocellular carcinoma, but the relation between survi

225 pican-3 (GPC3) is a promising new marker for hepatocellular carcinoma, but the reported values for se

226 loyment status, education status, history of hepatocellular carcinoma, diabetes, heart failure, atria

227 hotics listed for liver transplantation with hepatocellular carcinoma, even in geographic areas of re

228 nonalcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma, gallstones, acute pancreatitis

229 Whereas CD8(+) T-cell ablation accelerates hepatocellular carcinoma, genetic or pharmacological int

230 e (NAFLD), a common prelude to cirrhosis and hepatocellular carcinoma, is the most common chronic liv

231 tes, encephalopathy, and variceal bleeding), hepatocellular carcinoma, liver transplantation, and liv

232 ch lncRNA MALAT1 acts as a proto-oncogene in hepatocellular carcinoma, modulating oncogenic alternati

233 ad treatment interrupted at 17 months due to hepatocellular carcinoma, one patient had dose interrupt

234 rus, hepatitis B surface antigen positivity, hepatocellular carcinoma, or missing HCV RNA or FIB-4 sc

235 s, mental confusion, hepatic encephalopathy, hepatocellular carcinoma, severe anemia, untreated hypot

236 For patients with advanced hepatocellular carcinoma, sorafenib is the only approved

237 over, we show that USP21 is overexpressed in hepatocellular carcinoma, where it promotes BRCA2 stabil

238 he dichotomous nature of Gal-9 is evident in hepatocellular carcinoma, where loss of expression in he

239 r patients with unresectable, liver-confined hepatocellular carcinoma.

240 disease progression, including cirrhosis and hepatocellular carcinoma.

241 irst-line therapy for patients with advanced hepatocellular carcinoma.

242 use of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma.

243 development of diseases such as diabetes and hepatocellular carcinoma.

244 o those with chronic liver failure (CLF) and hepatocellular carcinoma.

245 r adjustment for risk factors not related to hepatocellular carcinoma.

246 that could lead to severe complications and hepatocellular carcinoma.

247 orld and often causes fibrosis/cirrhosis and hepatocellular carcinoma.

248 ere more likely to have lower MELDs and have hepatocellular carcinoma.

249 onic infections causing hepatic fibrosis and hepatocellular carcinoma.

250 risk of developing fibrosis, cirrhosis, and hepatocellular carcinoma.

251 ction, which may lead to liver cirrhosis and hepatocellular carcinoma.

252 HBV disease worse, including higher rates of hepatocellular carcinoma.

253 k of developing end-stage liver diseases and hepatocellular carcinoma.

254 s been shown to have relevance in diagnosing hepatocellular carcinoma.

255 ntial of nivolumab for treatment of advanced hepatocellular carcinoma.

256 survival following liver transplantation for hepatocellular carcinoma.

257 hronic inflammation to tumour development in hepatocellular carcinoma.

258 and duration of fatty liver disease-related hepatocellular carcinoma.

259 higher efficacy than etoposide for treating hepatocellular carcinoma.

260 ymphocyte-mediated regression of established hepatocellular carcinoma.

261 nals were observed in patients with advanced hepatocellular carcinoma.

262 adult chronic liver disease, cirrhosis, and hepatocellular carcinoma.

263 alities, including steatosis, hepatitis, and hepatocellular carcinoma.

264 gn hepatic tumors to progress into malignant hepatocellular carcinoma.

265 ar consequences of miR-122 downregulation in hepatocellular carcinoma.

266 ns greatly limited in cancers, especially in hepatocellular carcinoma.

267 role of SLC13A5 in the progression of human hepatocellular carcinoma.

268 n a population with abnormally high rates of hepatocellular carcinoma.

269 due to complications of liver cirrhosis and hepatocellular carcinoma.

270 triglycerides in hepatocytes, which leads to hepatocellular carcinoma.

271 genome instability, progeria and early onset hepatocellular carcinoma.

272 s C virus (HCV) is one of the main causes of hepatocellular carcinoma.

273 velopment of cirrhosis, hepatic failure, and hepatocellular carcinoma.

274 and its implications for the development of hepatocellular carcinoma.

275 rd Associated with Liver Transplantation for Hepatocellular Carcinoma; HALT-HCC) assessed the associa

276 Hepatocellular carcinomas (HCC) contain a subpopulation

277 More than 80% of hepatocellular carcinomas (HCCs) develop in fibrotic or

278 Hepatocellular carcinomas (HCCs) exhibit a diversity of

279 Human hepatocellular carcinomas (HCCs) expressing the biliary/

280 Global distribution of hepatocellular carcinomas (HCCs) is dominated by its inc

281 lar features of immune cells that infiltrate hepatocellular carcinomas (HCCs) to determine whether th

282 Human hepatocellular carcinomas (HCCs), which arise on a backg

283 with both the frequency and average size of hepatocellular carcinomas being elevated in Neil1(-/-) T

284 sed tumor ablation is successful in treating hepatocellular carcinomas, the necessity for multiple tr

285 LL3 and ARID1B, which are mutated in >50% of hepatocellular carcinomas, were also mutated in liver me

286 Finally, by comparing murine hepatocellular carcinomas, which developed in p53 wild-t

287 fects in acute-phase response, and increased hepatocellular damage, compared with control mice.

288 h HO-1 levels correlated with well-preserved hepatocellular function and enhanced SIRT1/LC3B expressi

289 ypothesized that Btk inhibition would reduce hepatocellular injury in a murine model of liver warm he

290 BTKB66 treatment ameliorated hepatocellular injury in a well-established model of liv

291 Drug-induced hepatocellular injury is identified internationally by a

292 Steatotic liver responds with increased hepatocellular injury when exposed to an ischemic-reperf

293 CD8 and L-selectin, but not CD4, ameliorated hepatocellular injury, confirming that CD8(+) cells are

294 uted to the absence of caspase-3 activity of hepatocellular interleukin 16 (IL-16) is no longer proce

295 in the regulation of PLIN2 and promotion of hepatocellular lipid accumulation is not well understood

296 id infiltrate, and can arise in the liver as hepatocellular or cholangiocarcinoma forms.

297 d real-time visualization and measurement of hepatocellular oxidant production during liver ischemia-

298 fall short of recapitulating the full mature hepatocellular phenotype.

299 Previous studies have reported mutations in hepatocellular transporters (ABCB4, ABCB11).

300 cule also exhibited increased ASGPR-directed hepatocellular uptake and prolonged retention compared t